Markets:

Overview

News

Currencies

International

Treasuries

CureVac N.V. - Ordinary Shares (NQ:CVAC)

4.640 -0.030 (-0.64%)

Streaming Delayed Price Updated: 2:26 PM EST, Jan 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CureVac N.V. - Ordinary Shares

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout ↗

October 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (...

Via Benzinga

Unusual Options Activity Insight: CureVac ↗

August 11, 2021

CureVac (NASDAQ:CVAC) shares experienced unusual options ...

Via Benzinga

54 Biggest Movers From Friday ↗

October 04, 2021

Check out these big penny stock gainers and losers Losers Spire Global, Inc.. (NYSE: SPIR) shares fell 43.3% to close at $7.10 on Friday. Spire Global, Inc....

Via Benzinga

Vaccine Stocks: Why MRNA, VXRT, CVAC and NVAX Stocks Need a Band-Aid Today ↗

October 01, 2021

Today, vaccine stocks are taking a massive hit as investors price in the potential effect of oral medications for Covid-19 on this sector.

Via InvestorPlace

Why Moderna, Novavax And Other COVID-19 Vaccine Stocks Are Plummeting ↗

October 01, 2021

The COVID-19 pandemic proved to be a boon for many biopharma companies that benefited from their foray into the development of vaccines and/or treatments against the novel...

Via Benzinga

Scientists Rapidly Advancing Cancer Vaccine Prospects Using Same Technology as Covid-19 Shots

September 17, 2021

Via FinancialNewsMedia

Breaking Down The Inflation Numbers Draws Attention To Oil Prices ↗

September 15, 2021

Oil futures (/CL) are up 1% this morning ahead of the crude oil inventories report. While the NY Empire State Manufacturing Index was nearly double forecast. However,...

Via Benzinga

CureVac Shares Fall After Cutting COVID-19 Vaccine Production Plans ↗

September 14, 2021

CureVac BV has canceled contract manufacturing deals for its experimental COVID-19 vaccine with two prospective partners.

Via Talk Markets

CureVac Shares Fall After Cutting COVID-19 Vaccine Production Plans ↗

September 14, 2021

CureVac BV (NASDAQ: CVAC) has canceled contract manufacturing deals for its experimental COVID-19 vaccine with two prospective partners. The Company would...

Via Benzinga

Why CureVac's Stock Is Down During Today's Session ↗

September 14, 2021

CureVac (NASDAQ:CVAC) shares are trading lower after the company announced its strategic decision to adjust the long-term footprint of the external European...

Via Benzinga

CureVac Streamlines European Network for mRNA Product Manufacturing

September 14, 2021

- CureVac right-sizes manufacturing network to adapt to changes in vaccine peak demands - Demand reassessed for first-generation COVID-19 vaccine candidate, CVnCoV, currently under regulatory review...

From CureVac

Via AccessWire

Topics Intellectual Property Regulatory Compliance

CureVac's CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet

August 31, 2021

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 31, 2021 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger...

From CureVac

Via AccessWire

Topics Intellectual Property Regulatory Compliance

Glaxo, SK Bioscience Start COVID-19 Vaccine Trial Against AstraZeneca Shot ↗

August 31, 2021

GlaxoSmithKline Plc (NYSE: GSK) has started Phase 3 clinical study for a COVID-19 vaccine candidate designed by South Korean drugmaker SK Bioscience Co. The...

Via Benzinga

CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic

August 30, 2021

- Findings in preclinical mouse models provide first direct proof of efficacy of HNF4A mRNA therapeutics in the treatment of liver fibrosis and cirrhosis - Further research aimed at optimizing mRNA...

From CureVac

Via AccessWire

Topics Death Intellectual Property Regulatory Compliance

Could CureVac's Canceled Deal Spell Trouble for Other mRNA Cancer Vaccines? ↗

August 27, 2021

It isn't likely.

Via The Motley Fool

Surprise! Here's the Cheapest COVID Vaccine Stock on the Market Right Now ↗

August 19, 2021

The least expensive COVID-19 vaccine stock right now isn't one of the leaders in the market -- at least not yet.

Via The Motley Fool

4 High-Yield Dividend Stocks to Boost Your Dividend Income ↗

August 17, 2021

Dividends paid by GlaxoSmithKline plc, Vector Group Ltd, Star Group, L.P., and Ennis, Inc translate to high yields at their current price levels.

Via Talk Markets

Boehringer Ingelheim Scraps Lung Cancer Program With CureVac ↗

August 16, 2021

CureVac NV (NASDAQ: CVAC) disclosed among the COVID-19 vaccine highlights that €465 million oncology partnership with Boehringer Ingelheim had been terminated...

Via Benzinga

Vaccine Stocks: The Latest News Moving BNTX, CVAC, NVAX Stocks Today ↗

August 16, 2021

Today, investors in vaccine stocks are seeing a lot of red, as investors seem to be taking some risk off the table ahead of Fed tapering.

Via InvestorPlace

Topics Economy

CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update

August 16, 2021

CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update - Continuation of corporate transformation into commercial-ready biopharma company-...

From CureVac

Via AccessWire

Topics Intellectual Property Regulatory Compliance

Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study

August 16, 2021

- Preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac's first-generation mRNA...

From CureVac

Via AccessWire

Topics Intellectual Property Regulatory Compliance

26 Stocks Moving in Thursday's Pre-Market Session ↗

August 05, 2021

Gainers Ensysce Biosciences, Inc. (NASDAQ: ENSC) shares rose 34% to $5.48 in pre-market trading after dropping around 15% on Wednesday. Ensysce Biosciences recently appointed...

Via Benzinga

EMA Starts Rolling Review Of Glaxo - Sanofi COVID-19 Vaccine ↗

July 20, 2021

EMA's human medicines committee has kicked off a rolling review of a COVID-19 vaccine from Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (...

Via Benzinga

Can CureVac Win Market Share With Only 48% Vaccine Efficacy? ↗

July 10, 2021

CureVac aims to become one of Europe's big suppliers.

Via The Motley Fool

Unusual Options Activity Insight: CureVac ↗

July 07, 2021

On Wednesday, shares of CureVac (NASDAQ:CVAC) saw unusual options activity. After the option alert, the stock price moved down to $59.8. Sentiment: BEARISH Option Type: SWEEP...

Via Benzinga

South Korea Negotiating With mRNA COVID-19 Vaccine Makers To Produce Up To 1B Doses: Reuters ↗

July 06, 2021

South Korea is reportedly in talks with mRNA vaccine makers, including Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA), to produce COVID-19 shots in the...

Via Benzinga

Here's Why You Should Avoid CureVac Stock Like the Plague ↗

July 04, 2021

Funds will not be safe if invested in this coronavirus stock.

Via The Motley Fool

Is CureVac a Bargain Bet on mRNA Vaccine Technology? ↗

July 04, 2021

CureVac shares have slipped more than 20% on bad news.

Via The Motley Fool

Topics Cannabis

The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision And Conference Presentations In A Light Week ↗

July 03, 2021

Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few COVID-19 disappointments,...

Via Talk Markets

The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision, Conference Presentations In A Light Week ↗

July 03, 2021

Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few...

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.